FP5C-16, RCi93

General#

Cell Line

hPSCreg Name RCi002-B
Alternative name(s)
FP5C-16, RCi93
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 3rd July 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Pfizer Limited - Pfizer (PFIZ)
Owner Stem Cell Research Laboratory
Distributors

External Databases

BioSamples SAMEA3106075
Cellosaurus CVCL_9S44
ECACC 66540050
EBiSC RCi002-B

General Information

Publications
Projects
* Is the cell line readily obtainable for third parties?
Yes

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Primary erythromelalgia
The donor is affected.
Synonyms
  • Primary erythermalgia
Genetic variants
2q24.3
Heterozygous
In the publication PMID:27099175, heterozygous point mutations were confirmed by Sanger sequencing: F1449V: TTC(F) >> GTG(V)

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105889

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? No
Has the donor been informed that participation will not directly influence their personal treatment? No
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet:
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? Yes
Details on restriction to research project Research use, not transplantation
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Policy for access to genetic information Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided:
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved?
Approval number B3291006
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved?
Approval number B3291006
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell type
erythroblast
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
  • normoblast
Source cell type (free text) Blood - PBMC erythroblasts

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 14

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
18 out of 20 cells normal, one cell 45,X,add(X)(q22),-11, one cell 45,XX,-22
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes